Navigation Links
Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
Date:9/1/2011

ROCKVILLE, Md., Sept. 1, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that President and CEO Richard Garr will present at the 2011 Stifel Nicolaus Annual Healthcare Conference on Wednesday, September 7 at 8:00 a.m. EDT. Garr will discuss the Company's opportunities and advancements in neural stem cell pharmaceuticals and cellular therapy, and will be providing an update on the ongoing ALS trial at Emory University.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

Garr will also present at the 2011 Rodman & Renshaw Annual Healthcare Conference on Tuesday, September 13 at 10:50 a.m. EDT.

The 2011 Stifel Nicolaus Annual Healthcare Conference will be held at the Four Seasons Hotel in Boston, September 7-9. For more information, see: www.stifel.com or http://www.tweisel.com/Stifel/ConferencesAndEvents/ .

The 2011 Rodman & Renshaw Annual Healthcare Conference will be held at The Waldorf=Astoria in New York City, September 11-13. For more information, see: http://www.rodmanandrenshaw.com/conferences?id=162 .

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major ce
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
2. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
3. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
4. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
5. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
6. Neuralstem Completes $5.25 Million Financing
7. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
8. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
10. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
11. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... TEL AVIV, Israel , May 5, 2015 ... that the Company was approved to continue trading ... companies. OTCQB Marketplace allows for ... an electronic broker-dealers. Investors can have real-time quotes ... The OTCQB Marketplace includes ...
(Date:5/5/2015)... , May 5, 2015  A group of biotechnology ... the Coma Research Institute, a non-profit organization dedicated to ... families suffering from disorders of consciousness.  ... http://photos.prnewswire.com/prnh/20150504/213779LOGO   ... consciousness, in which no voluntary actions can be initiated ...
(Date:5/5/2015)... Calif. , May 5, 2015 CytomX, ... of cancer, today announced that Sean McCarthy , ... Credit Suisse Antibody Day in New York ... 6. Dr. McCarthy will present an overview of CytomX,s ... Probody drug conjugate programs. About CytomX Therapeutics ...
(Date:5/5/2015)... -- Indianapolis-based medical device manufacturer NICO Corporation is seeing ... including the BrainPath® and Myriad™ technologies offering a ... and then removing affected tissue. More than 1,600 ... institutions throughout the United States ... 12 abstracts, three peer-reviewed publications, and seven presentations ...
Breaking Biology Technology:Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3
... Drug Offers Potential Treatment ... to Americans Suffering from IBS-C, BETHESDA, Md., Sept. 17 ... the supplemental,New Drug Application (sNDA) for lubiprostone (8 mcg, oral ... with,constipation (IBS-C) has been accepted for review by the U.S. ...
... 17 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) ... President, will present an overview of the Company,s ... Annual Investment Conference,in San Francisco. Dr. Henderson,s presentation ... am PT. Dr. Henderson,s presentation will be ...
... Tissue Provides Building-Block Cells for Muscle, Bone, ... ... BioLife Solutions,Inc. (OTC Bulletin Board: BLFS), a leading developer ... tissues, and organs, today announced that privately held Tissue,Regeneration Therapeutics ...
Cached Biology Technology:FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 2FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 3FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 4FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 5Keryx Biopharmaceuticals to Present at Bank of America Investment Conference 2BioLife Solutions' CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells 2BioLife Solutions' CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells 3
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ... Iris Recognition Market 2015-2019" report to their offering. ... market to grow at a CAGR of 23.5 percent ... the present scenario and the growth prospects of the ... calculate the market size, the report considers the revenue ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... doesn,t bed down with theatre, much less mate with ... explored in the recent production Heuschrecken [The Locusts] developed ... asks Arizona State University,s Manfred Laubichler and Gitta Honegger ... of the journal Science . "Scientists have ...
... WASHINGTON, Jan. 28, 2010 The U.S. Department ... the release of new satellite images depicting agricultural land ... crop year. The images, referred to as cropland data ... rotation patterns, land use changes, water resources and carbon ...
... The Genetics Society of America (GSA) is pleased ... distinguished service to the field of genetics. These ... the genetics community. The individuals who receive these ... recognition of the exceptional value of their work to ...
Cached Biology News:Scientists and cast of thousands swarm stage in Europe 2Scientists and cast of thousands swarm stage in Europe 3The Genetics Society of America announces its 2010 award recipients 2The Genetics Society of America announces its 2010 award recipients 3
Edited by D. Patel (1994) Comprehensive data on gel electrophoresis of proteins, nucleic acids, nucleoproteins and carbohydrates....
...
... Silver Staining Kit, 1. Select from ... and peptides on denaturing, native, and ... reproducibility with precast gels, buffer strips, ... to that of radioisotopes with ready-to-use ...
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
Biology Products: